Business Wire

FORE Biotherapeutics Presents Phase 1/2a Plixorafenib Data Demonstrating Prolonged Duration of Effect in BRAF Altered Thyroid Cancers at American Thyroid Association® 2025 ...

PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today presented new ...
ascopubs.org

Survival outcomes in radioactive iodine-refractory (RAIR) differentiated thyroid cancer (DTC) with BRAF mutation: A real-world study from the Spanish Taskforce for ...

Results of management of cervical lymph node metastases in differentiated thyroid carcinoma: Experience in an upper middle-income country. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Medical Xpress

Pre-surgical combination therapy boosts survival in patients with rare thyroid cancer

A pre-surgical combination therapy including pembrolizumab plus dabrafenib and trametinib (DTP) significantly improved survival in patients with rare BRAF V600E-mutated anaplastic thyroid cancer ...
ascopubs.org

Pilot study evaluating the addition of cemiplimab in BRAF-mutant anaplastic thyroid cancer after progression on dabrafenib and trametinib.

A retrospective study of pyrotinib for advanced salivary duct carcinoma (SDC) with positive HER2 expression. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does ...
Medscape

Is Thyroid Cancer a 'Good' Cancer? Experts & Patients Say No

Papillary thyroid cancer is widely known as the "good cancer." This term has been around for years and is used ubiquitously. Some think it's "appropriate" because the cancer is highly treatable and ...